Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatoses 2Neurofibroma, Plexiform 2Solid Tumor, Adult 1Neurofibromatosis 1 1Neurofibroma 1Melanoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

AZD 6244 4trametinib 2mirdametinib 2dabrafenib 2Everolimus 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neurofibroma, Plexiform × mirdametinib × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡